Balchem Corporation (BCPC)
NEUTRALファンダメンタル
71
株価
$179.24
時価総額
$5.79B
パート1 · 企業の価値
概要
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$1.09B
直近12か月(2026/6/30まで)
純利益
$164M
直近12か月(2026/6/30まで)
フリーキャッシュフロー
-
自己資本合計
$1.26B
負債合計
$429M
流動比率
2.66
利払い倍率
-
負債/EBITDA
0.65
一株当たり利益(EPS)
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$126.59
現在株価
$179.24
安全マージン
-41.6%
適正価値レンジ
$82.29 - $170.90
推定方法
バリュエーション指標
P/E レシオ
34.87
ROE
12.3%
P/B レシオ
4.34
P/FCF
-
粗利益率
36.3%
ROIC
10.9%
収益性レーダー
Value Creation (Economic Moat)
ROIC
10.9%
WACC
9.0%
ROIC − WACC
+2.0 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
ファンダメンタル分析基準
合格(17)
- EPS shows upward trend
- EPS CAGR 10.73%
- Price CAGR 8.01%
- ROIC 11.0%
- Gross Margin 36.3%
- Debt/Equity ratio
- Operating Margin 20.2%
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 12.8%
- Revenue Growth 5Y 8.1%
- Analyst Consensus 78% Buy
- Earnings Quality (OCF/NI) 1.34
- Share Dilution -0.3%
- Net Margin Trend 15.1% vs 14.5%
- Piotroski F-Score 9/9
不合格(6)
- P/B Ratio 4.34
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 0.9%
- PEG Ratio 2.72
データなし(5)
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
Piotroski F-スコア
財務健全性が高い
利益の質
高品質:利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Theodore Lee Harris | CEO, President & Chairman | 60 |
| Mr. Carl Martin Bengtsson | Executive VP, CFO, Treasurer and GM of Animal Nutrition & Health | 48 |
| Ms. Hatsuki Miyata J.D. | Executive VP, Chief Legal Officer & Secretary | 49 |
| Mr. M. Brent Tignor | Senior VP & Chief Human Resources Officer | 47 |
| Mr. Frederic Boned | Senior VP, Head of Digital Transformation & AI and GM of Human Nutrition & Health | 46 |
| Ms. Erin L. Gilson | VP & Chief Accounting Officer | - |
| Mr. Martin Luther Reid | Senior VP & Chief Supply Chain Officer | 58 |
| Mr. Job L. van Gunsteren | Senior VP & GM of Specialty Products | 48 |
| Mr. George Graham | Senior VP and Chief R&D Officer | 55 |
監査リスク
3
取締役会リスク
4
報酬リスク
4
株主権利リスク
7
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
Latest News
Recent headlines for BCPC, sourced from Markets Gazette.